CN106110423A - Female tire blood group incompatibility adsorbing therapy instrument - Google Patents
Female tire blood group incompatibility adsorbing therapy instrument Download PDFInfo
- Publication number
- CN106110423A CN106110423A CN201610540908.0A CN201610540908A CN106110423A CN 106110423 A CN106110423 A CN 106110423A CN 201610540908 A CN201610540908 A CN 201610540908A CN 106110423 A CN106110423 A CN 106110423A
- Authority
- CN
- China
- Prior art keywords
- blood
- adsorber
- ghost
- antibody
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000001383 blood group incompatibility Diseases 0.000 title claims abstract description 35
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 19
- 210000002381 plasma Anatomy 0.000 claims abstract description 76
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 33
- 239000000427 antigen Substances 0.000 claims abstract description 31
- 108091007433 antigens Proteins 0.000 claims abstract description 31
- 102000036639 antigens Human genes 0.000 claims abstract description 31
- 239000003463 adsorbent Substances 0.000 claims abstract description 23
- 229920000936 Agarose Polymers 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 11
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 8
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000006166 lysate Substances 0.000 claims abstract description 6
- 230000003204 osmotic effect Effects 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 53
- 239000008280 blood Substances 0.000 claims description 53
- 206010018910 Haemolysis Diseases 0.000 claims description 23
- 230000008588 hemolysis Effects 0.000 claims description 23
- 230000004087 circulation Effects 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 14
- 239000000499 gel Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000011543 agarose gel Substances 0.000 claims description 2
- 210000003850 cellular structure Anatomy 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000002156 adsorbate Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 208000007502 anemia Diseases 0.000 abstract description 9
- 230000002969 morbid Effects 0.000 abstract description 5
- 230000002706 hydrostatic effect Effects 0.000 abstract description 4
- 238000007792 addition Methods 0.000 abstract description 2
- 210000004700 fetal blood Anatomy 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 229920001817 Agar Polymers 0.000 description 17
- 210000003754 fetus Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 238000012544 monitoring process Methods 0.000 description 10
- 239000008272 agar Substances 0.000 description 9
- 230000023555 blood coagulation Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000002616 plasmapheresis Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 210000003677 hemocyte Anatomy 0.000 description 6
- 229940000351 hemocyte Drugs 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 206010000206 ABO incompatibility Diseases 0.000 description 3
- 208000021130 Bilirubin encephalopathy Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000006663 kernicterus Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920006221 acetate fiber Polymers 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019145 PO4.2H2O Inorganic materials 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002146 exchange transfusion Methods 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A61M1/3689—Chemical treatment by biological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- External Artificial Organs (AREA)
Abstract
nullThe present invention relates to a kind of female tire blood group incompatibility adsorbing therapy instrument in medical domain，It is characterized in that respectively using PB that osmotic concentration is 25 and 35mmol/L as lysate，Fully wash Rh positive O type erythrocyte and clean with normal saline，Make the ghost having dialysed hemoglobin but retain antigen performance active adsorption Rh antibody，Respectively be incubated after 100 DEG C dissolve 56 DEG C 0.9%、1.0%、1.1%、1.2%、1.3% agarose is made into the adsorbent of 95% ghost concentration，Take the most successively in the hydrostatic column that 55～65ml additions are made with high-biocompatibility material by agarose concentration，Make and make adsorbent therein form ghost from sample introduction end to sample outlet end to be uniformly distributed and agarose concentration adsorber from low to high，In order to the macromole morbid substance removing the Rh antibody in the blood plasma of accepted filtered absorption device and destroyed erythrocyte produces，Thus reach to avoid anemia of pregnant woman's Rh antibody enter fetal blood and alleviate the therapeutic purposes of the state of an illness.
Description
Technical field
The present invention relates to a kind of female tire blood group incompatibility adsorbing therapy instrument in medical domain, be mainly used in female tire blood group incompatibility pregnant
Anti-FE antibody and the removing of erythrocytolysis product in woman's blood plasma.
Background technology
Fetus inherits father and the gene element of each half of mother, and FE can carry the antigen from male parent,
The blood group showing as fetus is different from parent.After the erythrocyte of fetus enters the blood circulation of parent, the immunity of induction parent
System produces antibody, and antibody enters fetal circulation system through Placenta Hominis, in conjunction with FE, makes FE be broken
Bad, cause female tire blood group incompatibility hemolytic disease of fetus an d neonate.
Human erythrocyte's blood group has 26 kinds, the blood group such as including abo blood group, Rh blood group and MN, Lew, Kell and Fya, but
The blood group that can cause female tire blood group incompatibility Hemolysis is most common with Rh blood group and abo blood group.Rh blood group antigen are by No. 1 dyeing
On body, closely linked allele is determined by 3, has 6 kinds of antigens, i.e. C and c, D and d, E and e.Due to D antigen the earliest by
Finding, antigenicity is the strongest, therefore the most every D antigen positive person is referred to as the Rh positive, is referred to as Rh without D antigen person negative.Rh blood group
The antigenicity of antigen determines the order of severity of Hemolysis, and D antigen can cause serious Hemolysis, is secondly E antigen, is again
C, c and e antigen, the antigenicity of d antigen is the most weak, there is no anti-d antibody at present and finds.Frequency negative for Rh in China's Chinese Han Population
It is about 0.4%, and the frequency of the Northwest ethnic groups Rh feminine gender is up to more than 10%.
Although the incidence rate of ABO incompatibility is the highest, but fetus haemolysis incidence rate is the lowest, even if there is haemolysis, symptom is also
Relatively light, few generation bilirubin encephalopathy and edema, trimester of pregnancy is without special handling.Although and Rh blood group incompatibility is rare, but it causes mother
The severity extent ABO incompatibility to be overweighted of tire blood group incompatibility Hemolysis, so to the diagnosis of Rh blood group incompatibility and prevention extremely
Important.Rh blood group incompatibility produces the Rh antibody (the anti-D of IgG) of a large amount of anti-FEs due to parent, rear broken in entering fetus body
Bad substantial amounts of FE, makes fetus severe anemia, anoxia, heart failure, hepar damnification, hypoproteinemia, hydrosarca, breast
Water, ascites even Intrauterine Fetal Death.At non-neonate, there is the jaundice time early in Rh blood group incompatibility haemolysis relatively ABO incompatibility,
Early occur that after birth in 12 hours, majority occurred in 24 hours.Due to haemolysis produce a large amount of bilirubin can not in time from
Liver get rid of, make neonatal jaundice increase the weight of, substantial amounts of bilirubin penetrate into brain cell and cause bilirubin encephalopathy, often die from severe anemia,
Heart failure, bilirubin encephalopathy, mortality rate is the highest.
Although serious Hemolysis can be caused by destroying the erythrocyte of fetus after in Rh antibody entrance fetus body, but certain
A little anemia of pregnant woman also can carry out Rh (D) the positive red blood cell sensitization body of pre-anti-intrusion by injecting Rh antibody in advance, and then can prevent Rh
The generation of Hemolysis.Owing to current most countries has forbidden carrying out D antigen immune, the source of the anti-D of polyclone Ig with volunteer
The most extremely limited, and utilize the Epstein-Barr virus conversion human B lymphocyte secretion anti-D of Ig or Epstein-Barr virus to convert and combine cell fusion preparation
The anti-D of Ig, the anti-D of Ig of bone-marrow-derived lymphocyte strain or hybridoma cell strain secretion because using EBV conversion in vivo still suffer from much asking
Topic, as contained EBV has potential pathogenic；May be with the pathogen such as HIV and hepatitis virus；With hybridoma technology production
The anti-D of Ig is containing Mus source protein, easily cause allergic reaction or with the oncogene of Mus, so by directly injecting Ig in vivo
Anti-D prevents Rh Hemolysis to be just restricted.
Treatment to female tire blood group incompatibility Hemolysis mainly has pregnancy period plasmapheresis, fetal transfusion, termination the most clinically
Gestation and neonatal exchange transfusion are treated.Anti-D titer needs to consider intrauterine transfusion more than 32, and fetal transfusion includes that fetus intraperitoneal is defeated
Blood and the blood transfusion of fetus Ink vessel transfusing, be respectively provided with certain risk, and none be proved effectively；Hyperbilirubinemia of newborn person can use
The Drug therapy such as blue light illumination, immunoglobulin'intravenous, if desired Blood exchanging therapy, Blood exchanging therapy is still molten for treatment neonate
The main method of disorders of blood；During gestation, anti-D titer is more than 64, need to consider replacement therapy of blood plasma, pregnant woman blood plasma displacement be exactly
To filter hemocyte and the blood plasma of method separation anemia of pregnant woman in extracorporeal circulation path, remove blood plasma displacement liquid (the fresh ice with equivalent
Freeze blood plasma or 5% albumin) supplement feedback, each replacement amount 2 000～3 000ml, speed 20～30ml/min, treatment time
2～4h, every 1～3d treatment 1 time；Or take anemia of pregnant woman's whole blood about 400ml every time, remove its blood plasma about 300ml after low-temperature centrifugation, supplement
Amount homotype fresh plasma, the most defeated Autoerythrocyte (RBC).Plasmapheresis proportionally can reduce pathogenic with removed plasma volume
The titre (titer) of antibody, it is thus possible to extend fetus survival and growth and development time in parent, can postpone termination of pregnancy
Time, it is that the anemia of pregnant woman of female tire ABO, Rh or other blood group incompatibility prevents miscarriage the good selection in treatment in early days in clinic, has preferably
Curative effect, also without other untoward reaction.But plasmapheresis can only remove the partial antibody in blood, it is impossible to stop the continuation of antibody
Produce, the female tire blood group incompatibility Hemolysis occurred can not be reversed, need to carry out plasmapheresis incessantly just effectively, the suitableeest
The anemia of pregnant woman of fetus edema, or the homozygote person that spouse is pathogenic antigens was there is, particularly in gestation before 20～22 weeks for once
While removing part pathogenic antibody, the most together eliminate substantial amounts of blood plasma (multiple beneficial composition), although make with displacement liquid
Supplement, but cannot completely supply and be removed blood plasma and various beneficial thereof, and the displacement liquid measure substituted is big, expense is held high
Expensive, supplement allosome blood plasma and easily cause the various side effect such as infectious disease and infusion reaction, which limits generally carrying out of plasmapheresis.
So, only remove pathogenic antibody in the urgent need to one, do not remove blood plasma (multiple beneficial composition), without using plasmapheresis liquid
The replacement therapy of blood plasma new method of the female tire blood group incompatibility Hemolysis inexpensively, safely, having no side effect.
In gel, Ag-Ab precipitation was initially applied to study Liesegang's phenomenon, application in 1932 in 1905
In identifying bacterial isolates, nineteen forty-six Oudin carries out immunodiffusion in test tube, is used for analyzing antigen mixture, 1948 years
Elek and Ouchterlony establishes agar double diffusion test respectively, is used for identifying two or more antigen or antibody.Gel resists
The media gel agar of antigen-antibody precipitation or agarose are a kind of polysaccharide bodies containing sulfate, can be dissolved in water during high temperature,
Congeal into after cold gel, is internally formed the network structure of a kind of porous, and aperture is very big, can allow macromolecular substances (molecular weight
Up to more than million) pass freely through.The size in aperture further depends on agar concentration, and agar concentration is big, and aperture is relatively small, agar
Concentration is little, and aperture is relatively large.The aperture of 1% agar gel is about 85nm, owing to agar or agarose have good chemistry
Stability, after gel, water content is big, and transparency is good, and convenient sources is disposable, is therefore a kind of well dispersive medium.Antigen
General all below 200,000 with the molecular weight of antibody, basic in free diffusing in gel.When antigen and corresponding antibodies are through diffusion
After when meeting in gel, form antigen antibody complex, if both are suitable in place's ratio of meeting, then formed maximum compound
Thing.Owing to the molecular weight of complex increases, granule increases, thus does not continues to diffusion and produce precipitation, and this precipitation is formed for
One " specific barrier ", all same antigen or antibody molecule can not pass through, and the different molecule of character can lead to
Cross this barrier and continue diffusion, until forming the complex of themselves.So, the precipitation that synantigen is not formed is each
There is each position.This kind of reaction is the most agar gel diffusion, is the routine at present with known antibodies detection unknown quantity corresponding antigens
Laboratory diagnosis project, is generally mixed in a certain amount of goat-anti people's Ig antiserum composition in agar gel, makes containing specificity
The sero-fast agar plate of goat-anti people Ig, when serum to be checked spreads in agar plate, properly locates to occur at antigen and antibody ratios
In conjunction with, form macroscopic white precipitate and no longer spread, additionally produce anti-FE antibody when female tire blood group incompatibility
Time, in the presence of complement, cause hematoclasis after antibody and erythrocyte binding, produce the destruction product of relatively macromole, can be by certain
The micropore institute detention of a little particular sizes.But so far there are no according to above-mentioned Mechanism Design treatment blood group incompatibility Hemolysis.
Summary of the invention
In order to solve to attack for a long time the treatment problem of the female tire blood group incompatibility Hemolysis being unable to, present inventors have proposed the present invention.
The invention aims to provide female tire blood group incompatibility adsorbing therapy instrument；Another object is intended to provide the system of therapeutic instrument
Standby and application process.
The object of the present invention is achieved like this: preparation osmotic concentration is the PB lysate of the PH7.4 of 25 and 35mmol/L,
Alternately washing Rh positive O type erythrocyte cleaning with normal saline, makes and has dialysed hemoglobin but retain antigenicity and can have
Effect absorption Rh antibody ghost, respectively with rise carrier function be incubated after 100 DEG C dissolve 42 DEG C 0.9%,
1.0%, 1.1%, 1.2%, 1.3% agarose is made into the adsorbent of 95% ghost concentration, by agarose concentration from height to
Low take 55～65ml additions successively and can stop specific particle mesh screen with what high-biocompatibility material was made at setup of entrances and exits
Hydrostatic column, make the adsorbent being initially charged the most then add next time after being cooled to semi-solid gel, make and make in container
Adsorbent forms ghost from sample introduction end to sample outlet end and is uniformly distributed and agarose concentration adsorber from low to high, is conducive to
Plasma perfusion and molecular sieve and the effect of immune clearance, when the blood plasma separated in extracorporeal circulation flows through adsorber, Rh antibody
The ghost being fixed in adsorbent is combined into fixing immune complex, destroyed bib and in combination
The agar gel detention that molecular sieve is the least by nearly adsorber port of export concentration is the highest of macromole immune complex, remove
The blood plasma of morbid substance feeds back internal after adsorber leaches.
Rh antibody is the virulence factor of female tire Rh blood group incompatibility Hemolysis, and Rh (D) positive red blood cell is the natural of Rh antibody
Antigen, the present invention choose the positive O type erythrocyte of Rh (D) make with the dialysis of PB lysate remove be harmful to human body hemoglobin but
Retain the antigenicity of absorption Rh antibody and do not adsorb the ghost of the natural antibody of anti-A and anti-B, solid with specific concentration
Make adsorbent due to the agarose medium of special concentration, can occur to combine with the Rh antibody filtered in blood plasma and be formed fixing
Immune complex thus be eliminated, and the filter opening that agar gel is formed reduces along with increasing of agarose concentration, closely
The agarose concentration of adsorber import department is low, and filter opening is just big, beneficially the combination of plasma perfusion and ghost and Rh antibody, and
The concentration in nearly exit is the highest, and filter opening is the least, it is easy to detention Hemolysis erythrocyte destroys the fragment formed and therewith
The macromole immune complex being combined into, the mesh screen that can stop particular size microgranule arranged in adsorber exit also has
The effect of detention hematoclasis product, defines the double of specific immunity absorption and non-specific mechanical stop to morbid substance
Weight barrier, congeal into after the cooling of special agarose medium semisolid, is internally formed the network structure of even porous, is conducive to free anti-
Former and antibody and the uniform diffusion of blood plasma components, it is to avoid the dead space of blood plasma liquid stream, add ghost absorption Rh antibody
Uniformity and surface area, enhance the effect of adsorbing therapy, adsorbed the blood plasma after Rh antibody and leached and feed back body after adsorber
In, it is achieved that manually Rh antibody is transferred to external treatment from internal, is that one only removes pathogenic antibody, do not remove blood plasma and
Its multiple beneficial composition without use plasmapheresis liquid cheap, safely, female tire Rh blood group incompatibility Hemolysis of having no side effect
Treatment new method.
Detailed description of the invention
Fig. 1 is the female tire blood group incompatibility adsorbing therapy instrument application schematic diagram proposed according to the present invention.
Fig. 2 is the cut-away view of the plasma separator proposed according to the present invention.
Fig. 3 is the cut-away view of the adsorber proposed according to the present invention
In Fig. 1, one end of arterial blood line pipe (1) is connected with arteries, and the other end is through heparin pump (2) and blood pump
(3) being connected with plasma separator (4), plasma separator (4) is through blood plasma pump (6) and circulation line (7) adsorber in parallel with 2
(8), adsorber (9) be connected, be connected with circulation line (10), venous line (5) the most successively, the other end of venous line (5)
It is connected with vein blood vessel.
In Fig. 2,1 is plasma separator, and 2 is plasma separator inner chamber, and 3 is the micropore on plasma separator inner chamber tube wall, 4
Being the hemocyte that can not pass through micropore (3), 5 is the little molecule blood plasma components that can pass through micropore (3), and 6 is plasma separator exocoel,
7 is blood plasma flow export, and 8 is switchable valve.
In Fig. 3,1 is adsorber, the Rh positive ghost that 2 are fixed in agar gel, and 3 is to enter adsorber
Rh antibody, 4 is the antigen antibody complex that Rh antibody is formed by Rh positive blood shadow Cell binding, and 5 is that the agar containing micropore coagulates
Glue, 6 is hematoclasis product, including bib and and antibody conjugates thereof.
Below in conjunction with Fig. 1, Fig. 2 and Fig. 3, the embodiment of female tire blood group incompatibility adsorbing therapy instrument that the present invention proposes is made
Detailed description.
One, the preparation of adsorbent
1, the acquisition of Rh (D) positive red blood cell and main agents
(1) acquisition of Rh (D) positive red blood cell: 1. buy positive " O " type of fresh concentration Rh (D) from blood station, Zhejiang Province red carefully
Born of the same parents；2. positive " O " the type erythrocyte of the most in vitro discarded umbilical cord Rh (D) of neonate is taken.
(2) main agents: 30mmol/L PB buffer: solution A is 0.04mol/L Na2HPO4(Na2HPO4.12H2O
14.328g is dissolved in 1000ml deionized water, and room temperature storage is standby)；Second liquid is 0.04mol/L NaH2PO4
(NaH2PO4.2H2O 6.24g is dissolved in 1000ml deionized water, and room temperature storage is standby).Take solution A 81.0ml and second liquid respectively
19.0ml mixing the PB of 40mmol/L, on the basis of 40mmol/L PB buffer, then add deionized water dilution 0.75
Become 30mmol/L PB buffer again, be made into 25 and 35mmol/L with method in proportion.Anti-D standard substance and Rh (D) standard are red
Cell is purchased from Guangzhou Lian Tai Bioisystech Co., Ltd.
2, the preparation of Rh positive ghost
(1) the fresh Rh positive O type erythrocyte of q.s is taken, respectively under conditions of 4 DEG C and 37 DEG C, with 1500r/min
The centrifugal speed of × 5min, cleans erythrocyte 4～5 times with isopyknic normal saline, to remove the possible attachment of erythrocyte surface
Abo blood group and Rh blood group and other immune antibody or natural antibody.
(2) with 0.04mol/L Na2HPO4With 0.04mol/L NaH2PO4The osmotic concentration of preparation is 25 and 35mmol/L
The PB lysate of PH7.4, under the centrifugal condition of 4 DEG C and 2500r/min × 10min, alternately and repeatedly Washed Red Blood Cells, pass through
The alternate of osmotic concentration, promotes hemoglobin to give and is removed outside erythrocyte.
(3) finally clean until supernatant is colourless with normal saline, with blood harmful in erythrocyte of dialysing completely
Lactoferrin, precipitation is the ghost containing D antigen.
(4) detection of antigenicity: 1. ghost and anti-D standard substance 37 DEG C are hatched 5min, centrifuging and taking supernatant detects
Anti-D standard substance titer reduces numerical value and determines the antigenicity of ghost.Concrete grammar is: take 10, test tube, numbering 1 respectively
～10, the 1st pipe adds ghost precipitation 1.0ml, and other each pipes add normal saline 0.5ml, then inhale ghost from the 1st pipe
Precipitation 0.5ml joins the 2nd pipe, inhales 0.5ml to the 3rd pipe after mixing, is diluted to the 10th pipe, finally pipe sucking-off with same operation
0.5ml discards, and often pipe adds anti-D standard substance 0.5ml, hatches 5min for 37 DEG C, centrifugal after mix gently, so that complete coagulation, several to occur
Maximum dilution multiple without free cell represents the antigenicity of ghost, and extension rate is the biggest, and antigenicity is the strongest, adsorbs Rh
The ability of antibody is the strongest.Supernatant antibody titer can also be measured with Rh (D) normal erythrocytes and determine the antigen of ghost
Property；2. measuring supernatant antibody titer with Rh (D) normal erythrocytes, anti-D standard substance titer (known) deducts supernatant antibody effect
Valency is the antigenicity (titer) of ghost.Supernatant antibody titer detection method is: take 10 test tubes, respectively numbering 1～
10, each pipe adds normal saline 1ml, takes removal 1ml after supernatant 1ml joins the 1st pipe mixing and goes to the 2nd pipe, with same behaviour
Being diluted to the 10th pipe, finally pipe sucking-off 1ml liquid discards, serum 40 μ l Yu Rh (D) the normal erythrocytes 10 μ l that will have diluted
Mixing, hatches 10 minutes, centrifugal 5 minutes sentence read result, and the coagulation pipe of maximum dilution multiple is antigenicity (titer), and titer should
More than 1: 1500.
(5) content of hemoglobin detection: with hypotonic destruction ghost, with conventional chemical luminescence analysis or fluorescence analysis
Method, the content of hemoglobin in qualitative and detection by quantitative ghost, should be less than the reference value lower bound of human normal plasma.
(6) ghost form: examine under a microscope form and the integrity of ghost, should be in circle shadow, no-reflection.
(7) for cellular morphology in circle shadow, no-reflection, high sensitivity routine hemoglobin qualitative detection is negative, quantitatively
Detection, less than the reference value lower bound of human normal plasma, the ghost of absorption Rh antibody titer more than 1: 1500, is left and taken standby.
3, the preparation of adsorbent
Take Rh positive ghost prepared by the present invention, respectively to play being incubated 42 after 100 DEG C dissolve of carrier function
DEG C 0.9%, 1.0%, 1.1%, 1.2%, 1.3% agarose C1-4B normal saline be made into the suction of 95% ghost concentration
Attached dose.
Two, the preparation of adsorber
1, preparation principle
The active substance (aglucon) that can adsorb morbid substance is fixed on macromolecule carrier in the way of crosslinking or coupling
Make adsorbent, carry out occlusion with biological or that physics and chemistry is affine specific bond, remove corresponding morbid substance.Currently available work immunity
Adsorbent aglucon have protein A, specific antigen or antibody (anti-human IgG antibodies), C1q, polylysine, tryptophan, phenylpropyl alcohol ammonia
Acid etc.；Can be used as carrier has agarose gel, glucosan, silica dioxide gel, polyvinyl alcohol pearl, resin etc..Adsorbent should
Have specific selectivity, stable and recyclability, biocompatibility (nontoxic, ametaboly reaction, without physical-chemical reaction, do not swash
Complement alive and blood coagulation system).
The present invention is because the free Rh antibody in pregnant woman blood plasma enters fetal blood based on female tire Rh blood group incompatibility Hemolysis
Caused by destruction FE, and Rh antibody can be combined absorption, and conduct by corresponding native antigen i.e. Rh positive red blood cell
Congeal into after the agarose cooling of medium semisolid, is internally formed the even porous network structure of a kind of larger aperture, beneficially Rh
The uniform diffusion of antibody, Rh positive red blood cell therein is the native antigen of Rh antibody, plays the effect of absorption Rh antibody, specific dense
The gel pore of degree has the fragment after mechanical detention Hemolysis infant hematoclasis and macromole in combination resists
The effect of original antibody complex.
2, material is prepared
Select the high-biocompatibility material close with Human vascular endothelial, it is desirable to good biocompatibility, without complement activation,
NIP reacts, without leukocyte, platelet, blood oxygen pressure, the change of complement C 3 C5a.Require by covalency, be grafted, polymerization etc.
Method improves the uniformity of material surface, hydrophilic, minimizing to blood coagulation and the impact of oxidative stress.Parent is added at adsorber inner surface
Hydrogel, as solidified 2 methylacryoyloxyethyl phosphocholines-butyl methacrylate in cellulose acetate membrane, by controlling
Wet-spinning procedure and generate CA/PMB30, CA/PMB80 and CA/PMB30-80, biocompatibility can be improved.By some anticoagulant
Matter is solidificated in carrier or adsorber inner surface, and blood coagulation, reduction heparin consumption can be suppressed even to realize no-rod tractor, as by liver
Element is aggregated on polyacrylonitrile-polymine film, can reduce the anaphylaxis of allergic constitution；Heparin covalent is attached to polyethers
Sulfone surface, can keep the mechanical property of polyether sulfone and improve the anticoagulation function of adsorber inner surface.On cellulose acetate film altogether
Valency solidification linoleic acid film, maybe will be covalently bound to polyacrylic linoleic acid and be grafted onto polysulfone membrane surface, can have preferably
Histocompatibility and anticoagulant effect.
3, the specification of adsorber enclosure
Make the hydrostatic column that footpath, the end is little, footpath, top is big of 50mm × 60mm, or make square, infundibulate, volume about 200
～300ml, top and the bottom are equipped with cell screen cloth, and footpath, top sieve number is 500 mesh, and footpath, end sieve number is 50 mesh, liquid outlet
Place arranges the cell strainer that mesh number is 200 mesh, constitutes the second defence line preventing cell debris from entering circulation, liquid entrance
And it is provided with relief area, the beneficially stability of system circulation between mesh screen.
4, adsorber preparation method
Take the adsorbent of present invention preparation, take 55～65ml by agarose concentration the most successively and join with acrylic acid
In 50mm × 60mm hydrostatic column (adsorber enclosure) that ester etc high-biocompatibility material is made, it is desirable to the suction being initially charged
Attached dose be cooled to semi-solid gel after the most then add next time, make and make the adsorbent in container be formed from sample introduction end to sample outlet end
Ghost is uniformly distributed and agarose concentration adsorber from low to high.
Three, the preparation of plasma separator
1, preparation principle: prepare according to the molecular size of hemocyte and blood plasma components.Such as visible component (blood in blood of human body
Cell) size be: normocyte is about 7 microns (μm), is the discoid cell of concave-concave；Leukocyte is divided into 5 kinds, neutral
Granulocyte about 12 μm, eosinophilic granulocyte is more bigger, and basophilic granulocyte is close with neutrophilic granulocyte, small lymphocyte 6-8 μm,
Approximating with erythrocyte, mononuclear cell is maximum, about 15-20 μm.Platelet is disc, and diameter 1～4 microns are to 7～8 microns not
Deng, the platelet mean diameter of people is 2-4 micron, thick 0.5～1.5 micron.
2 prepare material: can be selected for poly-vinegar non-woven fabrics, acetate fiber, absorbent cotton etc., it is desirable to good biocompatibility, hardly
Activating complement, do not cause inflammatory reaction, do not cause the change of leukocyte, platelet, blood oxygen pressure, complement C 3, C5a.Can pass through
Covalency, be grafted, the method such as polymerization improves the structure of material, the regulation microinhomogeneities on surface, hydrophilic, minimizing to blood coagulation and
The impact of oxidative stress thus improve sieving adequacy and biocompatibility, the generation of minimizing complication.
3 specifications: for the profile of separator, can be prepared as cylindricality knot with the material such as acetate fiber or absorbent cotton as filter element
Structure, it is prepared as the shapes such as flat structure as filter element with materials such as poly-vinegar non-woven fabrics；By hemocyte to be separated and blood plasma components
Molecular size determines aperture.Plasma separator stable in properties involved in the present invention, good biocompatibility, height that permeability is high
Molecularly Imprinted Polymer makes hollow fibre type filter, hollow-fiber film a diameter of 270～370 μm, and film thickness is 50 μm, and aperture is
0.2～0.6 μm, fibre length is 13.5～26 μm.This hole is only permitted blood plasma and is filtered, but can stop all of cell component.
Four, the application of therapeutic instrument of the present invention
Extracorporeal circulation branch road need to be collectively constituted with associated components.
1, the component of extracorporeal circulation branch road and purposes
(1) adsorber: include ghost and agar gel medium, be used for removing Rh antibody, RBC fragment, Rh antibody with
The complex etc. that RBC fragment is formed.
(2) plasma separator: for washed corpuscles and blood plasma.
(3) sound pulse pressure monitoring: arterial blood pressure monitoring mainly in order to the stopping state of dynamic monitoring adsorber micropore, is additionally used
With monitoring extracorporeal circulation thrombosis, solidification and the change of pressure.When blood flow deficiency, arterial pressure will reduce；When having blood coagulation, thrombosis
Being formed, particularly during adsorber blockage of the micro orifice, arterial pressure will raise；Venous pressure monitoring is used for monitoring the pressure of pipeline blood backflow
Power, when adsorber blockage of the micro orifice, blood coagulation, thrombosis, blood flow deficiency and venous return syringe needle come off, venous pressure will
Declining, if the distortion blocking of bloody path return duct or backflow syringe needle occur blocking, venous pressure will raise.
(4) air monitering (Air Detector): be used for monitoring the air bubble of blood pathway, typically use ultrasonic listening
Principle, in order to avoid patient occurs air embolism to arrange.When having monitored air bubble, detecting system can drive dynamic,
Vein bloody path folder carrys out blocking blood flow, prevents the generation of danger.
(5) blood pump (Blood Pump): be used for promoting blood circulation being smoothed out with maintaining treatment, usual blood pump part
Often having rotary test speed function, to monitor the blood circumstance of patient, therefore blood pump runner sets with flute pitch and wants accurately, and
Need often to adjust, according to the situation of bloody path pump line, typically spacing is set as 3.2～3.3mm, can not be the most loose, otherwise can make
Blood flow detection is become to be forbidden；Also can not be too tight, otherwise can cause pipe breakage.
(6) heparin pump (Heparin Pump): heparin pump is equivalent to the micro-injection pump applied clinically, in order to continue to
Injecting heparin in sieving pipeline (patient blood), owing to the blood of patient circulates and air contact in vitro, is susceptible to blood coagulation
Phenomenon, uses heparin pump to be possible to prevent the generation of blood coagulation.
Additionally include temperature control system, liquid mixing system, off gas system, monitored conductivity system, ultrafiltration monitoring and leakage
The parts such as blood monitoring.In a word, on the basis of key constitution system of the present invention, be expected to be further development of automatization, hommization,
Personalization, modularity, automatically monitoring and regulation and control, liquid crystal display, judge the micro computer process such as alarm reason and ring off signal voluntarily
System.
2, the using method of therapeutic instrument of the present invention
(1) install: with sterile working's connecting components, each portion such as including plasma separator, adsorber and each circulation line.
(2) aerofluxus: with physiological saline solution topping up separator, adsorber and each circulation line, gets rid of separator, adsorber
And gas in circulating line, bubble, go through, confirm without use after gas, bubble.
(3) logical liquid: arterial blood line pipe 1 is connected the arteries of HIV sufferers, the most again row of going through
Gas is the most complete, and liquid stream is the most unobstructed, and avoids managing the pollution of interior flow liquid.
(4) anticoagulant: inject anticoagulant (heparin) from heparin pump to liquid stream, be 2500 ∪ or 20～30 ∪/kg for the first time.
(5) start: arterial blood line pipe (1) is connected the arteries of therapist, venous line (5) is connected therapist
Vein blood vessel, then opens blood pump, and blood flow is 100～150ml/min, such as Fig. 1, when arterial blood is through arterial blood line pipe
(1) entering plasma separator (4), the blood plasma separated arrives adsorber through circulation line (7) under the effect of blood plasma pump (6)
(8), blood plasma to be full of, about 10 minutes, begin paying out blood plasma, flow out through circulation line (10), synchronize to irrigate blood to adsorber (9)
Slurry, when the blood plasma in adsorber (8) has nearly flowed, starts again at perfusion blood plasma, and now adsorber (9) begins paying out blood plasma,
Two adsorbers in parallel (8), adsorbers (9) are alternately.Such as Fig. 2, when blood to be separated enters plasma separator (1)
During inner chamber (2), through the effect of valve (8), little molecule blood plasma and the composition (5) thereof that can pass through micropore (3) enter outside separator
Chamber (6), then flows out through plasma outlet port (7), and the hemocyte (4) that can not pass through micropore (3) flows out through valve (8).Such as Fig. 3,
When Rh antibody (3) enters adsorber (1), Rh positive ghost (2) being fixed in agar gel (5) is combined into antigen
Antibody immune complex (4) and no longer move down, erythrocytic destruction product (6), including bib and with Rh antibody
Conjugate can not be by footpath screen cloth at the bottom of gel pore and adsorber by detention, and the blood plasma after absorption separates with plasma separator
Hemocyte feeds back after converging.So until the plasma circulation amount (usually 9L) being previously set, treatment just ends.If joined
Set computer program control, whole therapeutic process is by computer control, and can detect duty at any time, use can convenient,
Automatization and safety.
Five, the checking of therapeutic instrument practical application
In order to verify effect of therapeutic instrument, the present invention devises the easily-testing of adsorber effect of therapeutic instrument critical component
Method: take prepared ghost, joins and is incubated after 100 DEG C dissolve at 42 DEG C of 1.0% standby agarose C1-4B
In, it is configured to the adsorbent of 95% ghost concentration；Take 2.5 × 300mm Westergren's blood sedimentation tube 9 of sterilizing, draw 95% blood
The adsorbent of shadow cell concentration, to 200mm scale, becomes semi-solid after adsorbent cooling；Buy the fresh ice in blood station, center, Zhejiang Province
Freezing blood plasma 200mL, another purchase Rh antibody (people's anti-D type serum dry powder standard substance, Guangzhou Lian Tai Bioisystech Co., Ltd), with newly
Blood slurry is made into 1: 200,1: 300,1: 600 antibody titer, and Rh (anti-D) titre detection method (with reference to description), enters routinely
One step detection confirms whether above-mentioned prepared antibody titer is consistent, and is referred to as (Rh) antibody (titre) before filter, respectively takes 10ml
Before filter, antibody is injected separately into the upper end blank pipe of 3 blood sedimentation tubes, after flowing through the adsorbent containing ghost of blood sedimentation tube lower floor,
Collecting effluent, be referred to as (Rh) antibody after filter, Rh (anti-D) titre detection method confirms titre routinely, more respectively by anti-after filter
Body is made to leach for the 2nd time in the adsorbent containing ghost, is so repeated 3 times filtration and antibody titer detection, result (table 1)
Illustrating, after Rh antibody filters simple adsorber, major part Rh antibody is contained the adsorbent of ghost, warp accordingly
1st time, the 2nd time, the 3rd time filter after, the average titer of Rh antibody respectively from filter before 1: 367 reduce to filter after 1: 183,1:
58,1: 29, illustrate that Rh antibody constantly by ghost adsorption removal, thus can reduce along with the increase filtering number of times
Anemia of pregnant woman's (neonate) blood plasma Rh antibody titer and treat the purpose of female tire blood group incompatibility Hemolysis.
Table 1 Rh antibody filters titre testing result (1/x) before and after the adsorbent containing ghost
Claims (10)
1. the female tire blood group incompatibility adsorbing therapy instrument for medical domain, it is characterised in that by Rh positive O of special proportioning
Type ghost and agarose gel are poured into exit and arrange the adsorber of mesh screen, make the sample introduction end of adsorber to sample outlet end shape
Become ghost to be uniformly distributed and agarose concentration layer distributed from low to high, constitute ghost immunoadsorption and gel
Micropore and screen of cleaner mechanical stop jointly purify barrier, in adsorbate outer circulation blood plasma, Rh antibody and erythrocyte are molten
Hydrolysis products.
Female tire blood group incompatibility adsorbing therapy instrument the most according to claim 1, it is characterised in that described special proportioning refer to
The ghost of 95% content is uniformly formulated in 0.9%～1.3% agarose C1-4B.
Female tire blood group incompatibility adsorbing therapy instrument the most according to claim 1, it is characterised in that from adsorber sample introduction end to going out
The agarose concentration of sample end divides 0.9%, 1.0%, 1.1%, 1.2%, 1.3%5 layers successively.
Female tire blood group incompatibility adsorbing therapy instrument the most according to claim 1, it is characterised in that described PB lysate by
81.0ml Na Han 0.04mol/L2HPO4Solution A and 19.0ml NaH Han 0.04mol/L2PO4Second liquid be made into 40mmol/L's
It is diluted to 25 and 35mmol/L with deionized water after PB.
Female tire blood group incompatibility adsorbing therapy instrument the most according to claim 1, it is characterised in that normal saline cleans erythrocyte
Refer to 4 DEG C and 37 DEG C each washings 2 times.
Female tire blood group incompatibility adsorbing therapy instrument the most according to claim 1, it is characterised in that the shell of described adsorber holds
Amassing is 200～300ml, and top and the bottom are equipped with cell screen cloth, and footpath, top sieve number is 500 mesh, and footpath, end sieve number is 50 mesh, liquid
Body exit arranges the cell strainer that mesh number is 200 mesh, is provided with relief area between liquid entrance and mesh screen.
Female tire blood group incompatibility Hemolysis therapeutic instrument the most according to claim 1, it is characterised in that described plasma separator is empty
Core fiber filter membrane a diameter of 270～370 μm, film thickness is 50 μm, and aperture is 0.2～0.6 μm, and fibre length is 13.5～26 μ
M, can filter blood plasma but can not filter all of cell component.
8. the preparation for female tire blood group incompatibility adsorbing therapy instrument adsorbent of medical domain, it is characterised in that to wait body
Long-pending normal saline respectively washs the positive O type erythrocyte of Rh (D) 2 times under conditions of 4 DEG C and 37 DEG C and 1500r/min × 5min,
Then replace Washed Red Blood Cells with the PB lysate of the PH7.4 that osmotic concentration is 25 and 35mmol/L and exist with normal saline
2500r/min × 10min, clean to supernatant under conditions of 4 DEG C colourless, precipitation be remove hemoglobin containing D antigen
Ghost, respectively with rise carrier function be incubated after 100 DEG C dissolve 42 DEG C 0.9%, 1.0%, 1.1%, 1.2%,
1.3% agarose C1-4B normal saline is made into the adsorbent of 95% ghost concentration.
9. according to claim 1-7 arbitrary described female tire blood group incompatibility adsorbing therapy instrument answering in preparing extracorporeal circulation apparatus
Include that one end of arterial blood line pipe (1) is through heparin pump (2) and blood pump (3) and blood plasma with, it is characterised in that described extracorporeal circulation
Separator (4) is connected, plasma separator (4) through blood plasma pump (6) and circulation line (7) adsorber (8) in parallel with two, adsorb
Device (9) is connected, and is connected with circulation line (10), venous line (5) the most successively.
Application the most according to claim 9, it is characterised in that when enabling the extracorporeal circulation apparatus shown in Fig. 1, tremulous pulse
Blood through arterial blood line pipe (1) enter plasma separator (4), the blood plasma separated under the effect of blood plasma pump (6) through circulation
Pipeline (7) arrives adsorber (8), blood plasma to be full of, about 10 minutes, begins paying out blood plasma, flows out through circulation line (10), synchronization
Irrigate blood plasma to adsorber (9), when the blood plasma in adsorber (8) has nearly flowed, start again at perfusion blood plasma, now adsorber
(9) beginning paying out blood plasma, two adsorbers in parallel (8), adsorbers (9) are alternately.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610540908.0A CN106110423B (en) | 2016-07-01 | 2016-07-01 | Female tire blood group incompatibility adsorbing therapy instrument |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610540908.0A CN106110423B (en) | 2016-07-01 | 2016-07-01 | Female tire blood group incompatibility adsorbing therapy instrument |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106110423A true CN106110423A (en) | 2016-11-16 |
| CN106110423B CN106110423B (en) | 2019-01-22 |
Family
ID=57282862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610540908.0A Active CN106110423B (en) | 2016-07-01 | 2016-07-01 | Female tire blood group incompatibility adsorbing therapy instrument |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106110423B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108732340A (en) * | 2018-06-04 | 2018-11-02 | 武汉纽康度生物科技股份有限公司 | A kind of chromatography buffer of removal red blood cell |
| CN109157694A (en) * | 2018-07-01 | 2019-01-08 | 翁炳焕 | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument |
| CN109157695A (en) * | 2018-07-19 | 2019-01-08 | 翁炳焕 | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975156A (en) * | 1975-11-10 | 1976-08-17 | Ortho Diagnostics, Inc. | Method and material for detecting and quantitating fetal erythrocytes in adults |
| CN101023101A (en) * | 2004-07-20 | 2007-08-22 | 西福根有限公司 | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
| US20120214176A1 (en) * | 2011-02-22 | 2012-08-23 | Graham Henry A | Detection of specific antigens in a population of antigens |
| CN104718552A (en) * | 2012-09-13 | 2015-06-17 | 多伦多大学理事会 | System and method for fetal and maternal red blood cell counting |
-
2016
- 2016-07-01 CN CN201610540908.0A patent/CN106110423B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975156A (en) * | 1975-11-10 | 1976-08-17 | Ortho Diagnostics, Inc. | Method and material for detecting and quantitating fetal erythrocytes in adults |
| CN101023101A (en) * | 2004-07-20 | 2007-08-22 | 西福根有限公司 | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
| US20120214176A1 (en) * | 2011-02-22 | 2012-08-23 | Graham Henry A | Detection of specific antigens in a population of antigens |
| CN104718552A (en) * | 2012-09-13 | 2015-06-17 | 多伦多大学理事会 | System and method for fetal and maternal red blood cell counting |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108732340A (en) * | 2018-06-04 | 2018-11-02 | 武汉纽康度生物科技股份有限公司 | A kind of chromatography buffer of removal red blood cell |
| CN109157694A (en) * | 2018-07-01 | 2019-01-08 | 翁炳焕 | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument |
| CN109157695A (en) * | 2018-07-19 | 2019-01-08 | 翁炳焕 | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106110423B (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101398768B1 (en) | Cell-adsorbing column | |
| CN106110421B (en) | Rhesus monkey erythrocytes absorber | |
| CN106267422B (en) | Rh blood group incompatibility haemolysis disease therapeutic apparatus | |
| WO2012142180A1 (en) | Methods to detect and treat diseases | |
| US20110094962A1 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| EP2585082A2 (en) | One step removal of selected molecules from body fluid and tissue | |
| CN106110423B (en) | Female tire blood group incompatibility adsorbing therapy instrument | |
| CN106267407B (en) | Female tire Rh blood group incompatibility blood purifying therapeutical instrument | |
| CN106110424B (en) | Female tire Rh blood group incompatibility immunoadsorption therapy instrument | |
| CN106267418A (en) | Female tire blood group incompatibility antibody adsorbing therapy instrument | |
| CN106267423B (en) | People's Rh positive red blood cell absorber | |
| CN106344986B (en) | Female tire blood group incompatibility treats absorber | |
| CN106267405B (en) | Female tire blood group incompatibility haemolysis disease therapeutic apparatus | |
| CN106267421B (en) | Female tire blood group incompatibility plasma purification device | |
| CN115975321A (en) | Hydrogel, filter material for removing white blood cells in pet blood and preparation method thereof | |
| CN109157694A (en) | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument | |
| JPH01249063A (en) | Apparatus and method for separating leucocyte from platelet concentrate | |
| CN109157692A (en) | People-people's cell merges the preparation of female tire blood group incompatibility treatment hybrid strain | |
| CN106178162B (en) | Treating AIDS organelle | |
| JP2021145918A (en) | Material for removing activated leukocyte-activated platelet complex | |
| CN106166311B (en) | A kind of plasma purification system and its application | |
| CN109157695A (en) | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody | |
| CN109157690A (en) | Monkey-people's cell merges the preparation of female tire blood group incompatibility treatment hybrid strain | |
| CN109157691A (en) | The preparation of monkey-mouse cell fusion mother's tire blood group incompatibility treatment hybrid strain | |
| CN109157693A (en) | The preparation of people-mouse cell fusion mother's tire blood group incompatibility treatment hybrid strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200821 Address after: 310006 No. 1, bachelor Road, Zhejiang, Hangzhou Co-patentee after: Shu Lan (Hangzhou) Hospital Ltd. Patentee after: WOMEN'S HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG University Address before: The 317300 Ring Road Zhejiang County of Xianju province to the north, Xianju County Hospital Patentee before: Weng Binghuan |